You are here: Industry Insights > Anixa

News List

Anixa Biosciences' Covid-19 Compounds Expected to be Effective Against the Delta Variant prnewswire
August 26, 2021
Anixa Biosciences, Inc. announced today that a genomic variant analysis indicates that its potential compounds may be even more effective against the Delta variant than the original wild type SARS-CoV-2.
Anixa and OntoChem to enter next stage of Covid-19 therapy development pharmaceutical-technology
April 07, 2021
Anixa Biosciences and OntoChem are set to enter the next stage of developing their potential anti-viral therapy for Covid-19 on obtaining results from a Proof of Concept (POC) animal study.
Anixa Biosciences, Moffitt Cancer Center File IND Application for Ovarian Cancer CAR-T Therapy americanpharmaceuticalreview
March 25, 2021
Anixa Biosciences announced an IND (Investigational New Drug) application for its ovarian cancer CAR-T (Chimeric Antigen Receptor T-cell) therapy has been filed with the U.S. Food and Drug Administration (FDA).
Anixa Biosciences Begins Animal Testing of Covid-19 Therapeutic Candidates americanpharmaceuticalreview
February 19, 2021
Anixa Biosciences announced animal testing has commenced with two proprietary compounds that have shown potency in in vitro studies.
Anixa, OntoChem COVID-19 Therapy Demonstrates Comparable Potency to Remdesivir americanpharmaceuticalreview
December 15, 2020
Anixa Biosciences and OntoChem GmbH have verified one of their recently discovered compounds is similar in potency to remdesivir, the only approved anti-viral drug against SARS-Cov-2. As previously announced, Anixa and OntoChem had identified multiple ...
Anixa, OntoChem Announce Identification of Additional Covid-19 Compounds americanpharmaceuticalreview
August 18, 2020
Anixa Biosciences announced that the company and its partner, OntoChem, have identified additional candidates through their in silico screening study.